In recent weeks, global searches for the traditional Chinese medicine Suxiao Jiuxin Wan have spiked by 200%, driven by viral social media claims about its emergency cardiovascular benefits. This surge, concentrated in Southeast Asia, the Middle East, and Latin America, has prompted regulatory scrutiny in multiple countries as the product lacks OTC drug approval in most markets. The incident highlights critical challenges for herbal medicine exporters and regulators alike.

Event Overview

As of April 2026, Suxiao Jiuxin Wan has seen unprecedented search volume growth internationally despite lacking classification as an approved cardiovascular emergency drug by major regulators including China's NMPA and the U.S. FDA. Currently registered only as dietary supplements or traditional herbs in some countries, the product now faces reevaluation of its classification standards—with Vietnam initiating special assessments and Saudi Arabia's SFDA mandating additional safety disclosures.

Impact on Key Sectors

Export Manufacturers

Companies face immediate compliance risks as registration categories (supplements vs. drugs) directly determine labeling requirements and permitted claims. Mismatches could trigger customs seizures.

Raw Material Suppliers

Increased scrutiny may delay active ingredient approvals, particularly for danshen and borneol—key components now under Vietnam's reassessment.

Distribution Channels

E-commerce platforms and physical retailers must verify product registrations to avoid penalties for selling unapproved drugs disguised as supplements.

Critical Action Points

Monitor Regulatory Shifts

Track updates from Vietnam's assessment (expected Q3 2026) and Saudi SFDA's new labeling rules (effective August 2026).

Audit Product Classifications

Reconfirm registration status in target markets—especially where social media-driven demand emerges unexpectedly.

Prepare Documentation

Compile clinical safety data proactively, as seen with Saudi Arabia's new requirements for traditional medicine imports.

Industry Perspective

This event signals growing tension between consumer-driven herbal product demand and regulatory frameworks. While not yet resulting in widespread bans, the coordinated responses from multiple regulators suggest a trend toward stricter enforcement for traditional medicine claims. Exporters should interpret this as a warning to align marketing with actual registration status.

Conclusion

The Suxiao Jiuxin Wan surge underscores the need for precise compliance in cross-border herbal trade. Rather than reacting to viral trends, businesses should focus on documented registration pathways and anticipate tighter claims regulation globally.

Sources

• China NMPA drug registration database (accessed April 2026)
• Saudi SFDA circular No. 2026-HERB-014
• Vietnam Ministry of Health notice (pending full publication)